A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers (CP104)

Arrow Therapeutics

Status and phase

Terminated

Phase 2

Phase 1

Conditions

Chronic Hepatitis C

Treatments

Drug: A-831

Study type

Interventional

Funder types

Industry

Other

Identifiers

CP104

Details and patient eligibility

About

The purposes of this study are:

to determine the safety and tolerability of multiple doses of A-831 at various doses
to determine how multiple doses of A-831 are distributed through the bloodstream
to determine if A-831 reduces the amount of Hepatitis C virus in the blood

Enrollment

36 estimated patients

Sex

Male

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Volunteers will be males of any race aged 18-60 years with a BMI between 18 and 32 kg/m2 at the time of the screening medical
Volunteers who have given their written informed consent to participate in the study
Volunteers who are willing and able to comply with the protocol and study procedures
Volunteers who have a diagnosis of chronic hepatitis C infection and are in good health (other than history of Hepatitis C infection)

Exclusion criteria